A team of researchers from City of Hope and The University of Texas M.D. Anderson Cancer Center has reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.
This article was originally published on MedicalXpress.com
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
© 2024 SimplyWell.ca